lp002
mAbexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 17, 2019 (NCT04755543)
Timeline
Indications
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04600947 | Phase 2 | Dec 30, 2020 | Chinese Academy of Medical Sciences, Government of China |
| NCT04740021 | Phase 2 | Dec 2, 2020 | Government of China |
| NCT04756934 | Phase 1 | Aug 20, 2020 | Government of China |
| NCT04755543 | Phase 1 | Jun 17, 2019 | Government of China |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 4 | 4 | 2 | 2019 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1